Suppression of Cholangiocarcinoma Cell Growth by Human Umbilical Cord Mesenchymal Stem Cells: A Possible Role of Wnt and Akt Signaling

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Liu, Juan ^a   Han, Guoqing ^a   Liu, Hui ^a   Qin, Chengyong ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; MYC PROTEIN; NITROPRUSSIDE SODIUM; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE INHIBITOR; SERINE; SOMATOMEDIN C; THREONINE; WNT PROTEIN; CULTURE MEDIUM; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN UMBILICAL CORD DERIVED MESENCHYMAL STEM CELL; IMMUNOBLOTTING; MESENCHYMAL STEM CELL; MOUSE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BILE DUCT TUMOR; CULTURE MEDIUM; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; INTRAHEPATIC BILE DUCT; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; TUMOR CELL LINE; UMBILICAL CORD;

ANIMALIA;

ANIMALS; APOPTOSIS; BETA CATENIN; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; UMBILICAL CORD; WNT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876978743     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062844     Document Type: Article

References (48)

1. Higashi M, Yamada N, Yokoyama S, Kitamoto S, Tabata K, et al. (2012) Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. Pathobiology 79(2): 101-106.
2. Blechacz B, Gores GJ, (2008) Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48: 308-321.
3. Nathan H, Pawlik TM, Wolfgang CL, Choti MA, Cameron JL, et al. (2007) Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 11: 1488-1496.
4. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
5. Pittenger MF, Martin BJ, (2004) Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 95: 9-20.
6. Karahuseyinoglu S, Cinar O, Kilic E, Kara F, Akay GG, et al. (2007) Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells 25(2): 319-331.
7. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, et a1 (2004) Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J NatI Cancer lnst 96: 1593-1603.
8. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, et al. (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65: 3307-3318.
9. Archuleta TD, Devetten MP, Armitage JO, (2004) Hematopoietic stem cell transplantation in hematologic malignancy. Panminerva Med 46: 61-74.
10. Gardner SL, (2004) Application of stem cell transplant for brain tumors. Pediatr Transplant 8: 28-32.
11. Smalley M, Ashworth A, (2003) Stem cells and breast cancer: A field in transit. Nat Rev Cancer 3: 832-844.
12. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, et al. (2006) Human mesenchymal stem cells exert potent antitumorigenic effects in a modeI of Kaposi's sarcoma. J Exp Med 203: 1235-1247.
13. Cho JA, Park H, Kim HK, Lim EH, Seo SW, et al. (2009) Hyperthermia-treated mesenchymal stem cells exert antitumor effects on human carcinoma cell line. Cancer 115: 311-323.
14. Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, et al. (2008) Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 18: 500-507.
15. Li L, Tian H, Chen Z, Yue W, Li S, et al. (2011) Inhibition of lung cancer cell proliferation mediated by human mesenchymal stem cells. Acta Biochim Biophys Sin (Shanghai) 43: 143-148.
16. Gauthaman K, Yee FC, Cheyyatraivendran S, Biswas A, Choolani M, et al. (2012) Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro. J Cell Biochem113: 2027-2039.
17. Seshareddy K, Troyer D, Weiss ML, (2008) Method to Isolate Mesenchymal-Like Cells from Wharton's Jelly of Umbilical Cord. Methods Cell Biol 86: 101-119.
18. Prockop DJ, Gregory CA, Spees JL, (2003) One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci USA 100: 11917-11923.
19. Kolligs FT, Nieman MT, Winer I, Hu G, Van Mater D, et al. (2002) ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with β-catenin defects and promotes neoplastic transformation. Cancer Cell 1: 145-155.
20. Liu H, Qin CK, Han GQ, Xu HW, Ren WH, et al. (2008) Synthetic chenodeoxycholic acid derivative, HS-1200, induces apoptosis of human hepatoma cells via a mitochondrial pathway. Cancer Lett 270: 242-249.
21. Kaiser MJ, Tiegs G, Neuhuber WL, (2003) Close apposition of dynorphin-positive nerve fibres to lymphocytes in the liver suggests opioidergic neuroimmunomodulation. Histochem Cell Biol 120: 213-221.
22. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, et al. (2006) Aberrant Wnt/β-catenin signaling in pancreatic adenocarcinoma. Neoplasia 8: 279-289.
23. Pasca di Magliano M, Biankin AV, Heiser PW, Cano DA, Gutierrez PJ, et al. (2007) Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One 2: e1155.
24. Giles RH, Van Es JH, Clevers H, (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24.
25. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, et al. (2007) Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 282: 11221-9.
26. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007) Mesenchymal stem cells within tumor stroma promote breast cancer metastasis. Nature 449: 557-563.
27. Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, et al. (2005) Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy.Cancer Sci. 96: 149-156.
28. Lu YR, Yuan Y, Wang XJ, Wei LL, Chen YN, et al. (2008) The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 7(2): 245-251.
29. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F 3rd (2011) Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cell 29: 11-19.
30. Prockop DJ, (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71-74.
31. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, et al. (2004) Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 01: 1345-1356.
32. McCleary-Wheeler AL, McWilliams R, Fernandez-Zapicol ME, (2012) Aberrant Signaling Pathways in Pancreatic Cancer: A Two Compartment View. Mol. Carcinog (511) (): 25-39.
33. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-12.
34. Shtutman M, Zhurinsky J, Simcha I, Albanese C, Pestell R, et al. (1999) The cyclinD1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522-7.
35. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, et al. (2003) Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 63: 728-34.
36. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, et al. (1999) The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 18: 2883-91.
37. Koh TJ, Bulitta CJ, Fleming JV, Dockray GJ, Varro A, et al. (2000) Gastrin is a target of the β-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest 106: 533-9.
38. Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K, (1986) An improved colorimetric assay for interleukin2. J Immunol Methods 93: 157-165.
39. Correa S, Binato R, Du Rocher B, Castelo-Branco MT, Pizzatti L, et al. (2012) Wnt/ß-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer (121) (): 303.
40. Kolligs FT, Bommer G, Goke B, (2002) Wnt/β-catenin/TCF signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 66: 131-44.
41. Song S, Mazurek N, Liu C, Sun Y, Ding QQ, et al. (2009) Galectin-3 mediates nuclear β-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3βactivity. Cancer Res 69: 1343-1349.
42. Schmitz KJ, Lang H, Wohlschlaeger J, Sotiropoulos GC, Reis H, et al. (2007) AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol 13 (48): 6470-7.
43. Yoon H, Min JK, Lee JW, Kim DG, Hong HJ, (2011) Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK) 1/2. Biochem Biophys Res Commun 405(3): 333-7.
44. Lu Z, Hunter T, (2004) Wnt-independent β-catenin transactivation in tumor development. Cell Cycle 3: 571-3.
45. Lu Z, Ghosh S, Wang Z, Hunter T, (2003) Down-regulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4: 499-515.
46. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA, (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378: 785-9.
47. Weston CR, Davis RJ, (2001) Signal transduction: signaling specificity-a complex affair. Science 292: 2439-40.
48. Mulholland DJ, Dedhar S, Wu H, Belson CC, (2006) PTEN and GSK-3β:key regulators of progression to androgen-independent prostate cancer. Oncogene 25: 329-37.